New Drugs Outperform Paxlovid – A Game Changer for COVID and Future Pandemics
Shionogi Announces Global Phase 3 Trial Demonstrates Post-Exposure Prophylactic Use of Ensitrelvir Prevents Symptomatic COVID-19
Shionogi just announced that their antiviral pill, ensitrelvir, significantly prevents COVID transmission!
Participants took the antiviral after known exposure.
FDA Could Soon Limit Use of Only Drug for COVID Prevention
Pemivibart (Pemgarda) should only be used for pre-exposure prophylaxis of COVID-19 in immunocompromised patients when the combined national frequency of SARS-CoV-2 variants with substantially reduced susceptibility to the drug is less than or equal to 90%, the FDA announced on Monday.
Pemivibart (Pemgarda) should only be used for pre-exposure prophylaxis of COVID-19 in immunocompromised patients when the combined national frequency of SARS-CoV-2 variants with substantially reduced susceptibility to the drug is less than or equal to 90%, the FDA announced on Monday.
Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial | Invivyd
PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in Exploratory Analysis Ongoing Phase 3 Clinical Trial May be useful for PRE-EXPOSURE PROPHYLAXIS (Prep) in immunocompromised & immunocompetent